1 domain / 2 areas / 1 specialization
Albert LabsCSE: ABRT
Very small Canadian biotech developing KRN-101, a natural psilocybin formulation for cancer-related psychological distress. Market capitalisation fell below C$300,000 in 2024, with minimal operating activity and limited financing capacity.
Development Programmes
1KRN-101 (Natural Psilocybin)
PsilocybinCancer-related psychological distress — single 25mg dose + psychotherapy. De facto paused since late 2023.
Programme Tracker
Palliative & End-of-Life Distress
FIH Phase 1 planned with iNGENu CRO in Melbourne (LOI signed Nov 2022) but not started. Originally targeted Q2 2023 start. No public updates since late 2023. Real World Evidence study planned in UK with Dr. Sara Tai (Manchester) as PI.
Milestones
Funding milestone
CompletedActual: Mar 1, 2022
Series A closed, CAD $4.7M raised; began trading on CSE as ABRT
Why it matters: Series A provided initial funding for preclinical completion and FIH trial preparation. Albert Labs uses a proprietary natural psilocybin extraction process from cultivated mushrooms, positioning KRN-101 as a botanical product.
Company milestone
CompletedActual: Nov 1, 2022
LOI signed with iNGENu CRO for Phase 1 FIH study in Melbourne, Australia; FIH targeted Q2 2023
Why it matters: CRO engagement in Australia leverages TGA's more accessible clinical trial pathway for psychedelics. However, the FIH trial was never initiated — no trial registration, dosing announcement, or data readout has been published.
Watch next: Trial initiation or formal discontinuation announcement
Recorded Events
Nov 1, 2022: Company milestone
Mar 1, 2022: Funding milestone
Quick Facts
- Type
- Public Biotech
- Ticker
- CSE: ABRT
- Lead Stage
- Pre-clinical
- Website
- Visit